Unlimited access to the most powerful analytical tools in finance.

Subscribe for $2
Overview
Profile
PRA Health Sciences Stock

PRA Health Sciences Stock PRAH

PRAH
US69354M1080
A12BHV

Price

165.21
Today +/-
+0
Today %
+0 %

PRA Health Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the PRA Health Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the PRA Health Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the PRA Health Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze PRA Health Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

PRA Health Sciences Stock Price History

DatePRA Health Sciences Price
7/1/2021165.21 undefined
6/29/2021165.21 undefined

PRA Health Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PRA Health Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PRA Health Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PRA Health Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PRA Health Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PRA Health Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PRA Health Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PRA Health Sciences’s growth potential.

PRA Health Sciences Revenue, EBIT and net profit per share

DatePRA Health Sciences RevenuePRA Health Sciences EBITPRA Health Sciences Net Income
2025e4.99 B undefined0 undefined647.95 M undefined
2024e4.58 B undefined0 undefined518.36 M undefined
2023e4.32 B undefined0 undefined518.36 M undefined
2022e3.97 B undefined0 undefined453.57 M undefined
2021e3.6 B undefined0 undefined388.77 M undefined
20203.18 B undefined283.9 M undefined197 M undefined
20193.07 B undefined366.8 M undefined243 M undefined
20182.87 B undefined317.3 M undefined153.9 M undefined
20172.26 B undefined264.3 M undefined86.9 M undefined
20161.81 B undefined208 M undefined68.2 M undefined
20151.61 B undefined165 M undefined81.8 M undefined
20141.46 B undefined56.8 M undefined-35.7 M undefined
2013991.3 M undefined43 M undefined-88.3 M undefined
2012699.7 M undefined47.1 M undefined-2.7 M undefined
2011634.8 M undefined55.9 M undefined17.3 M undefined
2010519.8 M undefined47.9 M undefined-100,000 undefined
2009455.9 M undefined26.5 M undefined-14.5 M undefined

PRA Health Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2009201020112012201320142015201620172018201920202021e2022e2023e2024e2025e
0.460.520.630.70.991.461.611.812.262.873.073.183.63.974.324.584.99
-14.0722.1610.2541.7747.2310.5612.2824.7427.096.793.8213.1010.228.975.948.93
40.8838.9235.6534.0530.8827.9030.3230.2029.3927.9028.5727.2724.1121.8820.0718.9517.39
18620222623830640748954766480187686800000
-14017-2-88-35816886153243197388453518518647
----111.764,300.00-60.23-331.43-16.0526.4777.9158.82-18.9396.9516.7514.35-24.90
57.357.357.357.357.342.963.264.565.866.36664.800000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The PRA Health Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PRA Health Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
201220132014201520162017201820192020
                 
109.272.285.2121.1144.6192.2144.2236.2506.3
184.9295338.8415.1439.1627568.1658.5843.9
3.125.642.40.91.62.92.711.3
000000000
2765.260.735.340.156.367.188.199
0.320.460.490.570.620.880.780.991.46
5175.872.980.787.6143.1154.8367.1372.8
03.21.21.30.30.4000
5.500000000
108.4699.8600.9533.9474783.8704.4638.6599.9
0.491.11.031.010.971.511.491.51.69
2.758.816.724.331.841.350.150.554.3
0.661.941.731.651.572.482.42.562.72
0.982.392.212.232.193.363.193.544.18
                 
0400600600600600700600600
0.330.490.820.830.880.910.961.011.14
-156.7-39.9-75.76.174.3161.2254.5243.3440.3
2.216.9-69.5-132.3-224.7-136.5-170.7-160.1-98.8
000000000
0.180.470.680.70.730.931.051.091.48
17.327.739.157.151.364.643.755.356.9
50.389.678.983.889.8259.3243.5295.4313.4
235333.1348.3389.1391.8527.4611.7552.7779.4
01000091.5088.891.3
3.48.90031.328.802525
0.310.470.470.530.560.970.91.021.27
0.451.250.920.890.81.231.081.141.16
26.7185.6106.381.773.7112.2100.778.563.5
22.926.740.524.826.2112.453.1218.5211.2
0.51.461.0710.91.451.241.441.43
0.811.931.541.531.462.422.142.452.7
0.982.392.212.232.193.353.183.544.18
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of PRA Health Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand PRA Health Sciences's financial health and stability.

Assets

PRA Health Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that PRA Health Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of PRA Health Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into PRA Health Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
nullnullnull201220132014201520162017201820192020
000-2-88-35816887154243197
000305096786978112114131
000-7-51-32-3-10-7511-23-20
0004657-22-6-35-2615-4747
00032562716815736-3371
000274480544848484240
00014461727474311177
703128992534152160220329253427
000-18-19-27-32-33-61-55-74-66
-9-17-18-18-1,079-11-71-34-687-55-73-233
0000-1,05915-38-1-62601-167
000000000000
00061789-333-40-215506-315172-22
000047033400731-25458
-0.04-0.01-0.01-0.041.08-0.01-0.04-0.10.51-0.32-0.090.08
000-1-50-6-2113-7-35-841
000-101-1310000000
000392310342343-4891270
000000000000
000000000000

PRA Health Sciences stock margins

The PRA Health Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PRA Health Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PRA Health Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PRA Health Sciences's sales revenue. A higher gross margin percentage indicates that the PRA Health Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PRA Health Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PRA Health Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PRA Health Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PRA Health Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PRA Health Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PRA Health Sciences Margin History

PRA Health Sciences Gross marginPRA Health Sciences Profit marginPRA Health Sciences EBIT marginPRA Health Sciences Profit margin
2025e27.29 %0 %12.98 %
2024e27.29 %0 %11.32 %
2023e27.29 %0 %11.99 %
2022e27.29 %0 %11.43 %
2021e27.29 %0 %10.8 %
202027.29 %8.92 %6.19 %
201928.59 %11.96 %7.92 %
201827.9 %11.05 %5.36 %
201729.41 %11.7 %3.85 %
201630.21 %11.48 %3.76 %
201530.32 %10.22 %5.07 %
201427.91 %3.89 %-2.45 %
201330.87 %4.34 %-8.91 %
201234.09 %6.73 %-0.39 %
201135.66 %8.81 %2.73 %
201039.02 %9.22 %-0.02 %
200940.97 %5.81 %-3.18 %

PRA Health Sciences Stock Sales Revenue, EBIT, Earnings per Share

The PRA Health Sciences earnings per share therefore indicates how much revenue PRA Health Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PRA Health Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PRA Health Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PRA Health Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PRA Health Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PRA Health Sciences Revenue, EBIT and net profit per share

DatePRA Health Sciences Sales per SharePRA Health Sciences EBIT per sharePRA Health Sciences Earnings per Share
2025e77.02 undefined0 undefined10 undefined
2024e70.7 undefined0 undefined8 undefined
2023e66.74 undefined0 undefined8 undefined
2022e61.24 undefined0 undefined7 undefined
2021e55.56 undefined0 undefined6 undefined
202049.13 undefined4.38 undefined3.04 undefined
201946.46 undefined5.56 undefined3.68 undefined
201843.32 undefined4.79 undefined2.32 undefined
201734.34 undefined4.02 undefined1.32 undefined
201628.09 undefined3.22 undefined1.06 undefined
201525.54 undefined2.61 undefined1.29 undefined
201434.02 undefined1.32 undefined-0.83 undefined
201317.3 undefined0.75 undefined-1.54 undefined
201212.21 undefined0.82 undefined-0.05 undefined
201111.08 undefined0.98 undefined0.3 undefined
20109.07 undefined0.84 undefined-0 undefined
20097.96 undefined0.46 undefined-0.25 undefined

PRA Health Sciences business model

PRA Health Sciences Inc. is a globally operating company for clinical research that was founded in 1982 and is headquartered in Raleigh, North Carolina. It specializes in supporting pharmaceutical and medical device manufacturers in the development and approval of drugs and medical devices. The business model of PRA Health Sciences is based on providing services throughout the entire clinical development process. This includes planning and conducting clinical trials, monitoring study centers, data collection and management, as well as statistics and medical consulting. The company's activities are divided into several divisions that focus on different areas of clinical development. The "Early Development Services" division offers services for the early clinical development of drugs and medical devices, including the conduct of Phase I studies and support for proof-of-concept studies. The "Clinical Development Services" division offers services for the later clinical development of drugs and medical devices, including the conduct of Phase II to Phase IV studies. The "Strategic Solutions" division offers a wide range of services for the entire clinical development process, including consulting, data analysis and interpretation, as well as the integration of technologies such as electronic medical records software. The "Product Registration" division offers services for the approval of drugs and medical devices, including support for submission of applications and the provision of regulatory affairs consulting services. One of the products offered by PRA Health Sciences is the "Lifetree Clinical Research" software platform, which is used for the management of clinical trials. Lifetree offers features for data management, project collaboration, and reporting, allowing users to access extensive amounts of data in real-time. PRA Health Sciences has a broad customer base including pharmaceutical and biotech companies, medical device manufacturers, and contract research organizations. The company has offices in more than 80 countries and employs approximately 18,000 people worldwide. In 2020, PRA Health Sciences was acquired by ICON plc, another globally operating company for clinical research. The acquisition is intended to expand ICON's global presence and service areas, enabling the company to offer a broader range of services in clinical development to its clients. Overall, PRA Health Sciences is a company for clinical research that offers a wide range of services for the development of drugs and medical devices. With its broad customer base, comprehensive range of services, and global presence, it is an important component of the clinical research industry and is expected to continue to play a crucial role in the development of new drugs and medical devices. PRA Health Sciences is one of the most popular companies on Eulerpool.com.

PRA Health Sciences SWOT Analysis

Strengths

1. Strong Reputation: PRA Health Sciences Inc has established a solid reputation in the pharmaceutical research industry for its high-quality services and expertise.

2. Global Presence: The company operates in multiple countries, allowing it to offer its services to a wide range of clients and access diverse markets.

3. Extensive Experience: With years of experience, PRA Health Sciences Inc has developed an in-depth understanding of the drug development process, enabling them to provide valuable insights and accelerate time-to-market for their clients.

4. Technological Advancements: The company leverages advanced technologies in its research and clinical trial operations, enabling efficient data collection, analysis, and reporting.

Weaknesses

1. Dependency on Key Clients: PRA Health Sciences Inc relies heavily on a small number of major pharmaceutical companies for a significant portion of its revenue. Any loss of these key clients could impact its financial stability.

2. Reliance on External Factors: The company's success is influenced by external factors such as government regulations, market conditions, and funding availability, leaving it vulnerable to changes beyond its control.

3. Talent Retention: Retaining top talent in a competitive industry can be challenging, and PRA Health Sciences Inc needs to ensure it can attract and retain skilled professionals to maintain its competitive edge.

Opportunities

1. Growing Demand for Clinical Research: The increasing need for drug development and clinical trials presents an opportunity for PRA Health Sciences Inc to expand its client base and increase revenue.

2. Emerging Markets: Expanding into emerging markets provides the company with new growth possibilities, as these regions offer untapped potential and a growing healthcare industry.

3. Partnerships and Collaborations: Collaboration with pharmaceutical companies, research institutions, and regulatory authorities can strengthen PRA Health Sciences Inc's capabilities, broaden its network, and foster innovation.

Threats

1. Intense Competition: The pharmaceutical research industry is highly competitive, and PRA Health Sciences Inc faces competition from both established players and emerging firms.

2. Regulatory Challenges: Changing regulations and compliance requirements in different countries can pose challenges for the company's operations and increase costs.

3. Economic Downturns: During economic downturns, pharmaceutical companies may reduce their research and development budgets, which could impact PRA Health Sciences Inc's revenue and growth opportunities.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

PRA Health Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

PRA Health Sciences historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

PRA Health Sciences shares outstanding

The number of shares was PRA Health Sciences in 2024 — This indicates how many shares 64.8 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PRA Health Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PRA Health Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PRA Health Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PRA Health Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for PRA Health Sciences.

Most common questions regarding PRA Health Sciences

What values and corporate philosophy does PRA Health Sciences represent?

PRA Health Sciences Inc represents a strong commitment to integrity, excellence, and innovation in the field of clinical research. The company's corporate philosophy is centered around delivering quality solutions to its clients and improving patient outcomes through cutting-edge technology and scientific expertise. PRA Health Sciences Inc strives to provide reliable data and insights that help accelerate the development of life-saving therapies. With a focus on collaboration and customer satisfaction, PRA Health Sciences Inc consistently seeks to exceed industry standards and drive positive change in the healthcare sector through its dedication to ethical practices and patient-centric approach.

In which countries and regions is PRA Health Sciences primarily present?

PRA Health Sciences Inc is primarily present in various countries and regions around the world. With a global presence, the company operates in North America, Europe, Asia-Pacific, Latin America, and Africa. PRA Health Sciences Inc offers its comprehensive range of clinical development services and solutions in these regions, catering to the diverse needs of pharmaceutical and biotech companies. As a leading global contract research organization, PRA Health Sciences Inc has established a strong foothold in these key markets, ensuring its expertise and services are accessible to clients worldwide.

What significant milestones has the company PRA Health Sciences achieved?

PRA Health Sciences Inc has achieved several significant milestones throughout its history. Some notable achievements include expanding its global presence by establishing offices in key markets, serving a vast range of therapeutic areas, and consistently delivering innovative solutions to the pharmaceutical industry. Additionally, PRA Health Sciences Inc has received multiple awards and recognitions for its commitment to excellence in clinical research and expertise in data-driven insights. With a strong track record of successful partnerships and collaborations, the company continues to drive transformative advancements in healthcare and contribute to the overall improvement of patient outcomes.

What is the history and background of the company PRA Health Sciences?

PRA Health Sciences Inc. is a global contract research organization (CRO) specializing in clinical research and drug development services. The company was founded in 1982 by a group of former employees from the U.S. Food and Drug Administration, and it has since grown to become a leading player in the CRO industry. PRA Health Sciences Inc. offers a wide range of services to pharmaceutical and biotechnology companies, including clinical trial management, data management, regulatory affairs, and consulting services. With its extensive expertise and global presence, PRA Health Sciences Inc. continues to make significant contributions to the advancement of medical research and the development of new therapies.

Who are the main competitors of PRA Health Sciences in the market?

The main competitors of PRA Health Sciences Inc in the market include QuintilesIMS Holdings Inc (now IQVIA), ICON plc, Covance Inc, and Charles River Laboratories International Inc. These companies also operate in the Contract Research Organization (CRO) industry, providing similar clinical development and laboratory services. However, PRA Health Sciences Inc distinguishes itself through its expertise in clinical research, data analytics capabilities, and efficient project management, which have established its strong market position.

In which industries is PRA Health Sciences primarily active?

PRA Health Sciences Inc is primarily active in the healthcare industry.

What is the business model of PRA Health Sciences?

The business model of PRA Health Sciences Inc is centered around providing a wide range of clinical research services to pharmaceutical and biotech companies. PRA Health Sciences offers a comprehensive suite of solutions including clinical development, data management, biostatistics, regulatory affairs, and consulting services. By leveraging its expertise and global capabilities, PRA Health Sciences helps clients navigate the complex process of developing innovative drugs and therapies. With a focus on delivering high-quality results and optimizing efficiencies, PRA Health Sciences plays a critical role in accelerating the pace of drug development and improving patient outcomes.

What is the P/E ratio of PRA Health Sciences 2025?

The PRA Health Sciences P/E ratio is 16.52.

What is the P/S ratio of PRA Health Sciences 2025?

The PRA Health Sciences P/S ratio is 2.15.

What is the Quality Investing of PRA Health Sciences?

The Quality Investing for PRA Health Sciences is 6/10.

What is the revenue of PRA Health Sciences 2025?

The expected PRA Health Sciences revenue is 4.99 B USD.

How high is the profit of PRA Health Sciences 2025?

The expected PRA Health Sciences profit is 647.95 M USD.

What is the business model of PRA Health Sciences

PRA Health Sciences Inc is a globally operating company that focuses on innovation and technology to conduct advanced research. PRA operates in more than 80 countries and offers a wide range of product development services in the fields of pharmaceuticals, biotech, and medical technology. The company divides its offerings into four divisions: - Product Development Services - Strategic Solutions - Early Development Services - Data Solutions & Decentralized Trials Product Development Services provide a comprehensive range of clinical development and regulatory consulting services, such as clinical trials, data-driven projects, and a comprehensive medical writing office. PRA's Strategic Solutions focus on optimizing clinical development to ensure more efficient and cost-effective measures. With benchmarking, process foundations, performance improvement programs, etc., customers benefit from faster research development and a significant improvement in competitiveness. Early Development Services provide professional support to capture the alignment and risks of clinical trials early on. This helps improve the success rate of clinical trials and more effectively capture the potential of product candidates. Data Solutions & Decentralized Trials help companies streamline processes, digitize offerings, and rely on technological advances and decentralized studies. PRA focuses on providing its customers with proprietary technology, data, and analysis capabilities, such as software like the PRA® Xchange EDC system or the innovative PRA® Health Harmony platform. In practice, this means that PRA Health Sciences offers its customers a comprehensive range of product development and management services to bring innovative products to market while minimizing risks and costs. As a result, product risks are identified early on, and the effectiveness of development programs is improved. PRA Health Sciences' business model is based on scientific expertise and a wide range of technology services. Through the use of advanced data analysis methods, extensive experience in dealing with regulatory requirements, and a comprehensive network of professionals, PRA offers its customers a range of services from planning to marketing products. The company is committed to solving the challenges of biotech and pharmaceutical customers by offering a wide range of services tailored to the different needs of customers, including productive quality controls, projects, data management, and a wide range of consulting services. Over the years, PRA Health Science has built its reputation on the continuous continuation of innovation and quality, which means that customers can expect significant benefits in managing their product portfolios, comprehensively and with high quality.

What is the PRA Health Sciences dividend?

PRA Health Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does PRA Health Sciences pay dividends?

The dividend cannot currently be calculated for PRA Health Sciences or the company does not pay out a dividend.

What is the PRA Health Sciences ISIN?

The ISIN of PRA Health Sciences is US69354M1080.

What is the PRA Health Sciences WKN?

The WKN of PRA Health Sciences is A12BHV.

What is the PRA Health Sciences ticker?

The ticker of PRA Health Sciences is PRAH.

How much dividend does PRA Health Sciences pay?

Over the past 12 months, PRA Health Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PRA Health Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of PRA Health Sciences?

The current dividend yield of PRA Health Sciences is .

When does PRA Health Sciences pay dividends?

PRA Health Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PRA Health Sciences?

PRA Health Sciences paid dividends every year for the past 0 years.

What is the dividend of PRA Health Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PRA Health Sciences located?

PRA Health Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von PRA Health Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PRA Health Sciences from 6/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/29/2025.

When did PRA Health Sciences pay the last dividend?

The last dividend was paid out on 6/29/2025.

What was the dividend of PRA Health Sciences in the year 2024?

In the year 2024, PRA Health Sciences distributed 0 USD as dividends.

In which currency does PRA Health Sciences pay out the dividend?

The dividends of PRA Health Sciences are distributed in USD.

All fundamentals about PRA Health Sciences

Our stock analysis for PRA Health Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PRA Health Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.